MPM Medical Acquires FDA Clearance for Collagen Devices

MESQUITE, Texas—MPM Medical announced an expansion of its United States manufacturing capabilities with the acquisition of a full collagen manufacturing platform and the associated Food and Drug Administration (FDA) 510(k) clearance for surgical collagen devices. This expansion significantly enhances MPM Medical’s ability to serve advanced wound care, surgical and private-label partners with high-quality, American-made collagen products.

This announcement follows last week’s national intrduction of MPM Medical’s Collagen At-Home Wound Care Kits and Proprietary Wound Care Portal.

Beginning Jan. 1, 2026, the company’s collagen production will operate out of MPM Medical’s 100,000-square-food FDA-registered facility in Mesquite, Texas. The expansion includes collagen processing technology, United States Pharmacopeia-grade compounding and several high-capacity lyophilizers which the company said will increase output for both branded products and growing private-label demand.

MPM Medical’s collagen portfolio now includes:

• MetaMatrix Antibacterial Surgical Collagen Powder
• ACM Surgical Collagen Pads
• TripleHelix advanced wound Care Collagen Powder, Pads, and Ropes
• At-home collagen wound care kits

All collagen is U.S.-made, non-hydrolyzed and derived from Type I bovine sources without added chemicals or chemical crosslinking—resulting in naturally low-endotoxin, low-pH, and highly biocompatible formulations suitable for surgical environments.

MPM Medical’s Mesquite, Texas manufacturing campus features:

• Class 8 cleanrooms
• Advanced lyophilizers
• FDA device-registration
• cGMP compliance
• Full microbiology and analytical testing labs
• Converting, packaging, sterilization and regulatory support
• End-to-end private-label manufacturing solutions
   

“With supply chain instability and rising global manufacturing costs, the health care market is demanding trustworthy, U.S.-made collagen more than ever,” said Marissa Ransdell, director of marketing at MPM Medical. “This expansion positions MPM Medical to meet that demand with higher quality control, reduced lead times and unmatched flexibility for private-label partners.”

“By bringing surgical and wound care collagen manufacturing fully in-house, we can innovate faster, scale production responsibly, and provide our partners with reliable, FDA-cleared solutions,” said Sudheer Kancherla, CEO. “This is a major milestone not just for MPM Medical, but for every clinician and company seeking dependable, American-made collagen.”

MPM Medical is now accepting inquiries from:

• Surgical centers and hospitals
• Wound care distributors
• OEM device manufacturers
• International health care organizations